ArthroCare Announces 510K Clearance for Periodontal Device.SUNNYVALE, Calif.--(BUSINESS WIRE)--Aug. 5, 1996--ArthroCare Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARTC ARTC Arthrocare Corp (stock symbol) ARTC Australian Rail Track Corporation ARTC Air Route Traffic Control ARTC Association de la Recherche Theatrale au Canada ARTC Andean Root and Tuber Crops ) today announced it has received 510(k) clearance, or determination of substantial equivalency, from the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ), which provides ArthroCare with regulatory clearance to market its periodontal device, which is under development. Hira Thapliyal, ArthroCare's President and Chief Executive Officer said, "We are encouraged that 510(k) clearances continue to come in a timely manner. The FDA's action on our periodontal device brings to seven the number of 510(k)s granted ArthroCare. We have now received clearances to market products for all six major joints of the body, as well as for urological and periodontal indications. Our focus in 1996 remains on the arthroscopic orthopedic market, and we believe we are well positioned to enter new markets in future years under several different scenarios, including possible distribution partnerships with interested third parties." This press release includes forward looking statements that involve risks and uncertainties including, but not limited to, quarterly fluctuations in results, the management of growth, the competitive environment and risks as detailed from time to time in the Company's Securities and Exchange Commission filings, including the Company's Quarterly Report on Form 10-Q Form 10-Q See 10-Q. dated May 10, 1996. ArthroCare Corporation designs, develops, manufactures, and markets arthroscopic surgical equipment that ablates soft tissue with minimal damage to surrounding healthy tissue, and simultaneously achieves hemostasis hemostasis /he·mo·sta·sis/ (he?mo-sta´sis) (he-mos´tah-sis) 1. the arrest of bleeding by the physiological properties of vasoconstriction and coagulation or by surgical means. 2. . The Company's long-term strategy includes applying its proprietary technology to a range of other soft tissue surgical procedures in the fields of urology urology Medical specialty dealing with the urinary system and male reproductive organs. It traces its origin to medieval lithologists, itinerant healers who specialized in surgical removal of bladder stones. , gynecology, dermatology, and plastic, oral and general surgery. The Company is headquartered at 595 North Pastoria Avenue, Sunnyvale, California, 94086. Telephone number is 408/736-0224. CONTACT: ArthroCare Corporation Larry Tannenbaum, 408/736-0224 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion